Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiosurgery vs Chemotherapy in Recurrent Glioblastoma
NCT05718466Phase 3Completed
- Sponsor
- Henry Ford Health
- Start
- Nov 2010
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in glioblastoma multiforme (GBM), sponsored by Henry Ford Health. Primary endpoint: Local Tumor Control at 2 months. Started Nov 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05718466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718466.